Pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders

Abstract

A use of (S)-(−)-α-ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment of particular diseases and new pharmaceutical compositions comprising (S)-(−)-α-ethyl-2-oxo-1-pyrrolidineacetamtide.

1 - 20 . (canceled)  
     
     
         21 . A pharmaceutical composition comprising levetiracetam and an amount of at least one compound inducing neural inhibitation mediated by the GABA A  receptors.  
     
     
         22 . The pharmaceutical composition of  claim 21  wherein the at least one compound inducing nueral inhibition mediated by the GABA A  receptors is selected from the group consisting of benzodiazepines, 1,4 benzodiazepines, 1,5 benzodiazepines, barbiturates, steroids, valproate, vigabatrin, tiagabine, and pharmaceutical acceptable salts thereof.  
     
     
         23 . The pharmaceutical composition of  claim 21 , wherein the at least one compound is selected from the group consisting of valproic acid, valproate, valpromide, valproate pivoxil, sodium valproate, semi-sodium valproate, divalproex, clonazepam, chlordizepoxide, diazepam, clobazam, phenobarbital, pentobarbital, vigabatrin, tiagabine and pharmaceutical acceptable salts thereof.  
     
     
         24 . The pharmaceutical composition of  claim 21 , wherein the amount of the at least one compound inducing neural inhibition mediated by the GABA A  receptors would not be therapeutically effective if administered alone.  
     
     
         25 . The pharmaceutical composition of  claim 24 , wherein the amount of the compound inducing neural inhibition mediated by the GABA A  receptors is reduced by a factor 3 to 15 with respect to usual effective therapeutic doses.  
     
     
         26 . The pharmaceutical composition of  claim 24 , wherein the amount of the compound inducing neural inhibition mediated by the GABA A  receptors and the amount of levetiracetam is in a ratio between 2 and 15.  
     
     
         27 . The pharmaceutical composition of  claim 21  wherein the amount of levetiracetam is up to 2.5 times lower than the normal effective dose for mono-administration.  
     
     
         28 . The pharmaceutical composition of  claim 21  wherein the compound is valproate administered in an amount between 70 mg and 180 mg.  
     
     
         29 . A method for treating a patient administered with an amount of at least one compound for inducing neural inhibition mediated by the GABA A  receptors, which if administered alone would not be therapeutically effective, comprising administering to such a mammal a therapeutically effective amount of levetiracetam, whereby the compound for inducing neural inhibition mediated by the GABA A  receptors is rendered therapeutically effective.  
     
     
         30 . A method for treating a disease chosen among epilepsy, alcohol withdrawal, tremor, bipolar disorder, mania, obsessive compulsive disorder, panic disorder, anxiety and anxiety disorders, depression, migraine, headache, pain disorders, ischemia and head trauma, comprising administering to a mammal afflicted with such a condition a therapeutically effective amount of the composition of the  claim 21 .  
     
     
         31 . The method of  claim 30  wherein the at least one compound inducing nueral inhibition mediated by the GABA A  receptors selected from the group consisting of valproic acid, valproate, valpromide, valproate pivoxil, sodium valproate, semi-sodium valproate, divalproex, clonazepam, chlordizepoxide, diazepam, clobazam, phenobarbital, pentobarbital, vigabatrin, tiagabine and pharmaceutical acceptable salts thereof.  
     
     
         32 . The method of  claim 30  wherein the at least one compound inducing nueral inhibition mediated by the GABA A  receptors selected from the group consisting of benzodiazepines, 1,4 benzodiazepines, 1,5 benzodiazepines, barbiturates, steroids, valproate, vigabatrin, tiagabine, and pharmaceutical acceptable salts thereof.  
     
     
         33 . The method of  claim 30  wherein the amount of the at least one compound inducing neural inhibition mediated by the GABA A  receptors would not be therapeutically effective if administered alone.  
     
     
         34 . The method of  claim 33 , wherein the therapeutically effective amount of the compound inducing neural inhibition mediated by the GABA A  receptors is reduced by a factor about 3 to 15 with respect to usual effective therapeutic doses.  
     
     
         35 . The method of  claim 33  wherein the amount of the compound inducing neural inhibition mediated by the GABA A  receptors and the amount of levetiracetam is in a ratio between 2 and 15.  
     
     
         36 . The method of  claim 30  wherein the amount of levetiracetam is up to 2.5 times lower than the normal effective dose for mono-administration.  
     
     
         37 . The method of  claim 30  wherein the compound is valproate administered in an amount between 70 mg and 180 mg.  
     
     
         38 . A method of selectively potentiating the therapeutic effect of a compound inducing neural inhibition mediated by the GABA A  receptors without increasing undesired side effects associated therewith which comprises co-administration of an amount of valproate which if administered alone would not be therapeutically effective, with an amount of levetiracetam effective in producing a therapeutic effect.  
     
     
         39 . A method for treating a patient administered with a non effective amount of at least one compound inducing neural inhibition mediated by the GABA A  receptors comprising administering to such a mammal a therapeutically effective amount of levetiracetam.  
     
     
         40 . The method of  claim 39  wherein the amount of levetiracetam is up to 2.5 lower than the normal effective dose for mono-administration.